CASO CLINICO Il paziente naϊve ad alta viremia Rapido sviluppo di resistenza ad EFV dopo solo 4 mesi di terapia.

Slides:

Advertisements

Similar presentations

Emerging patterns of drug resistance and viral tropism in cART-naïve and failing patients infected with HIV-1 subtype C Thumbi Ndung’u, BVM, PhD Associate.

Advertisements

The new guidelines Dr Francois Venter Reproductive Health and HIV Research Unit University of the Witwatersrand Feb 2010.

2nd Line ART Considerations for Resource-Limited Settings

HIV AND HIV MUTANTS E. Chigidi and E. Lungu University of Botswana Private Bag 0022 Gaborone, Botswana.

ANTIRETROVIRAL THERAPY Dr. Samuel Mwaniki (BPharm., MSc TID, UoN) University of Nairobi ISO 9001: Certified

Case Discussion: HIV resistance and salvage regimens The 3 rd HIV-NAT Symposium Series Wasana Prasitsuebsai, MD, MPH 25 th July 2013.

WHO Guidelines for treatment monitoring Nathan Ford Dept of HIV/AIDS World Health Organization.

Critical issues for Adults with HIV: Presentation of Systematic reviews and Main recommendations WHO 2013 ARV Guidelines Launch Dr. Meg Doherty, WHO, Geneva.

Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents December 2009 AETC NRC Slide Set.

Track B Workshop Controversies in the Management of HIV-positive Adults: A Case-Based Approach Sasisopin Kiertiburanakul, MD, MHS Associate Professor Department.

Young person with multi-class resistance: follow-up and management (with perspectives from well-resourced and resource-limited settings) Gareth Tudor-Williams.

11 HIV and contraception – complex issues for safe choice: the latest recommendations from the World Health Organization (WHO) Mary Lyn Gaffield, Sharon.

The Unique Resistance Profile of Tipranavir Dr Kevin Curry Boehringer Ingelheim, Bracknell, UK.

HIV Resistance Testing Clinical Implications Cyril K. Goshima, M.D. Director, AIDS Education Project June, 2009.

Welcome to UW I-TECH HIV/AIDS Clinical Seminar Series Treatment Failure, Resistance, and 2 nd line ART in Resource-Limited Settings Chris Behrens, MD May.

Switch to TDF/FTC/RPV - SPIRIT Study. SPIRIT study: switch PI/r + 2 NRTI to TDF/FTC/RPV STR  Design TDF/FTC/RPV STR 24 weeks 48 weeks Primary Endpoint.

1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.

MATEC Catherine Creticos, M.D. Medical Director

Future ART options for HIV-infected children exposed to maternal HAART Lee Kleynhans Experts Roundtable June 2008.

Global HIV Resistance: The Implications of Transmission

Nurses SOAR! Training Curricula Series For More Information and Inquiries:

Failure Therapy VIRAL RESITANCE ADHERENCE!!!!!!!!!!! DRUG INTERACTION.

2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents Summary of WHO Rapid Advice December 2009 Source: WHO HIV/AIDS Department.

When to Initiate ART in Adults and Adolescents (2009 WHO Guidelines) Target PopulationClinical conditionRecommendation Asymptomatic Individuals (including.

1 Advantages and risks for a child to be exposed to the triple prophylaxis during pregnancy and breastfeeding What is the best for the child ? Pr C. Courpotin.

1 Review of Antiretroviral Therapy in Adults HAIVN Harvard Medical School AIDS Initiative in Vietnam.

1 ARV Drug Resistance HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Regimen Selection to Support a “Public Health” Approach Anthony Amoroso, MD Assistant Professor of Medicine University of Maryland School of Medicine Institute.

1 Introduction to ARV Therapy HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.

Comparison of NNRTI vs PI/r  EFV vs LPV/r vs EFV + LPV/r –A5142 –Mexican Study  NVP vs ATV/r –ARTEN  EFV vs ATV/r –A5202.

Key1 ARV Treatment Guidelines for a Public Health Approach Product Selection for HIV Treatment Vincent Habiyambere February 2006.

On the protease gene, no major mutation was detected. However, many minor mutations, feature of the non B strains, were present and the most important.

Comparison of PI vs PI  ATV vs ATV/r BMS 089  LPV/r mono vs LPV/r + ZDV/3TCMONARK  LPV/r QD vs BIDM M A5073  LPV/r + 3TC vs LPV/r + 2 NRTIGARDEL.

Prevention and Care Dr S Charalambous WHO guidelines.

Washington D.C., USA, July 2012www.aids2012.org Changing Patterns of NRTI and PI Resistance Mutations Between 2006 and 2011 in ART experienced SA.

Rationale and Uses For a Public HIV Drug Resistance Database Bob Shafer, MD Professor of Medicine and by Courtesy Pathology (Infectious Diseases)

Antiretroviral targets in the viral life cycle Viral Replication and Drug targets.

N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Treatment-Experienced Patients in Resource- Limited Settings Susan M. Graham Assistant Professor, Medicine.

Slides Presented During Q & A. Expected Events in Untreated Patients Over 5 Years a Taiwan Observational Cohort Study and Safety Cohort b Chen CJ et al.

THE 6 TH NATIONAL SCIENTIFIC CONFERENCE ON HIV/AIDS MONITORING OF HIV DRUG RESISTANCE IN CHILDREN RECEIVING FIRST LINE ANTIRETROVIRAL THERAPY AT TWO CHILDREN.

Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Comparison of PI vs PI  ATV vs ATV/r BMS 089  LPV/r mono vs LPV/r + ZDV/3TCMONARK  LPV/r QD vs BIDM M A5073  LPV/r + 3TC vs LPV/r + 2 NRTIGARDEL.

HAIVN Harvard Medical School AIDS Initiative in Vietnam

Basics of Human Immunodeficiency Virus (HIV) Brian Rybarczyk, PhD University of North Carolina- Chapel Hill.

Profili di resistenza e barriera genetica dei nuovi trattamenti antiretrovirali Carlo Federico Perno Catania 10 Novembre 2015.

Date of download: 6/27/2016 Copyright © 2016 American Medical Association. All rights reserved. From: HIV-1 Drug Resistance Profiles in Children and Adults.

WHO 2013 Consultative Meeting Tawanna Hotel October 15, 2013.

Switch to PI/r monotherapy

Antiretroviral Therapy (ART)

Phylogenetic relationships of HIV-1 Pol RT strains

Introduction Results Objectives Methods Conclusion Funding

Switching to TDF-FTC from ABC-3TC for Hyperlipidemia ROCKET II

ARV-trial.com Switch to MVC MARCH Study 1.

Clinical and virologic follow-up in perinatally HIV-1-infected children and adolescents in Madrid with triple-class antiretroviral drug-resistant viruses

Giới thiệu về điều trị ARV

Chapter 17a HIV infection and AIDS.

Cases from the Clinic(ians): Case-based Panel Discussion

Results of round 1 of the Delphi survey

Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine K. Theys, R.J. Camacho,

Forecasting for ARVs medicines

ART Use in Selected PEPFAR Countries Forecasting for ARVs to 2010 November 7-8, 2005 Rational Pharmaceutical Management Plus.

Switch to DRV/r monotherapy

Comparison of NNRTI vs PI/r

F. Canducci, B. Barda, E. Ceresola, V. Spagnuolo, M. Sampaolo, E

Comparison of PI vs PI ATV vs ATV/r BMS 089

CASO CLINICO Il paziente naϊve ad alta viremia.

Comparison of PI vs PI ATV vs ATV/r BMS 089

CASO CLINICO Il paziente naϊve con resistenze al basale.

Resistance in the age of Integrases

Presentation transcript:

CASO CLINICO Il paziente naϊve ad alta viremia Rapido sviluppo di resistenza ad EFV dopo solo 4 mesi di terapia

On December 2011 Viremia: copies/ml CD4: 19 cells/µl Risk Factor Heterosex Clinical Case : ID Patient infected with HIV-1 CRF01_AE Age 43 Sex F CDC stage C3 I Seropositivity December 2011 in out DECEMBER 2011 – APRIL 2012 TDF+TFC+EFV GRT April 2012 PR: K20R, M36I, L63P, L89I, I93L RT: K103N, Y188H/Y in out Other pol mutations PR: T12I/T, I13V, E35D, N37D, R41K, K43R, H69K RT: E6D, V35T, T39K, K43E, F61F/L, D121H, K122E, I142V, S162A, K173I, Q174K, D177E, Q207A, R211S, V245E, A272P, V276I, T286A, E291D, V292I, I293V, E312T, I326V, Q334R, G335D GRT December 2011 PR: K20R, M36I, L63P, L89I, I93L RT: NONE Other pol mutations PR: I13V, Q18H/Q, E35D, N37D, R41K, K43R, H69K RT: E6D, V35T, T39K, K43E, D121D/H, I142V, S162A, K173I, Q174K, D177E, G196EG, I202IV, Q207A, R211S, V245E, A272P, V276IV, T286A, E291D, V292I, I293V, E312T, I326V Rapid appearance resistance to TDF and EFV after only four months of therapy

PR ATV/r DRV/r FPV/r IDV/r LPV/r NFV SQV/r TPV/r Total: RT 3TC ABC AZT D4T DDI FTC TDF EFV ETR NVP RPV Total: Mutation scoring* for the protease * Stanford Algorithm ( Mutation scoring* for the reverse transcriptase GRT December 2011 RT 3TC ABCAZTD4TDDIFTCTDFEFVETRNVPRPV K103N Y188H Total: GRT April 2012 PR ATV/r DRV/r FPV/r IDV/r LPV/r NFV SQV/r TPV/r Total: Susceptible virus Virus low level of resistance Virus intermediate resistance Virus high level of resistance Risk Factor Heterosex Clinical Case : ID Patient with HIV-1 CRF01_AE subtype Age 43 Sex F CDC stage C3 I Seropositivity December 2011